Agree completely - however I have a gut feel that the Angleman trial will be the key.
If PH replicates PMS, then it's genuinely outstanding and really exciting but you could still make a reasonable argument that there is an element of luck, small trial (sample size) etc. There is some wriggle room to downplay the results and upside possibilities,
If you have 3 trials that knock it out of the park then I think the potential is undeniable and you can't make any logical arguments for not throwing the kitchen sink at this to get your hands on it.
I think your comments "beneficial for people with other disorders both within and without of the autism spectrum" is absolutely on point!!
The penny will drop in my view and big pharma will be going back over the clinical data and assessing the drug and running the numbers on additional treatment opportunities.
Ann: 2023 Annual Report to shareholders, page-193
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.96 |
Change
0.260(2.05%) |
Mkt cap ! $1.655B | |||
| Open | High | Low | Value | Volume |
| $13.02 | $13.06 | $12.90 | $3.620M | 278.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 279 | $12.95 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.97 | 2532 | 8 |
View Market Depth
| Last trade - 12.02pm 17/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |